NURSING DOMAIN
Published December 20, 2023 | Version v1
Journal article Open

Advances in Drug Therapy for Rheumatoid Arthritis: A Comprehensive Overview

Authors/Creators

Description

Rheumatoid arthritis (RA) is a chronic autoimmune disorder manifested by inflammation of the joints, resulting in pain, swelling and joint damage. Non-steroidal anti-inflammatory drugs (NSAIDs) normally manage RA symptoms by decreasing inflammation and receiving pain. Whatever it may be, their long term use is often restricted because of the potential side effects on the gastro intestinal system and cardio vascular risks. Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate are frequently prescribed first _ line treatments, targeting immune system dysfunction. Janus Kinase (JAKs) plays a major role in immune response and hematopoiesis. These enzymes transduce signals particularly from cytokines and growth factors, enhancing communication between cells of the immune system. Treatment of RA includes dermatological conditions, hematological disorders, inflammatory bowel disease (IBD) and Rheumatoid arthritis. Finally it is concluded that from traditional NSAIDs to cutting _ edge biologics and JAK inhibitors, the field continues to advance, facilitating hope for improved outcomes and a better quality of life for individuals living with Rheumatoid arthritis.

Files

Advances in Drug Therapy for Rheumatoid Arthritis -Formatted Paper.pdf

Files (423.7 kB)

Additional details

References

  • 1. Klareskog, L., Rönnelid, J., Saevarsdottir, S., Padyukov, L., & Alfredsson, L. (2020). The importance of differences; On environment and its interactions with genes and immunity in the causation of rheumatoid arthritis. Journal of Internal Medicine, 287(5), 514-533.
  • 2. Smolen, J.S., Aletaha, D., McInnes, I.B. (2016). Rheumatoid arthritis. Lancet, 388(10055), 2023-2038.
  • 3. Bullock, J., Rizvi, S. A., Saleh, A. M., Ahmed, S. S., Do, D. P., Ansari, R. A., & Ahmed, J. (2019). Rheumatoid arthritis: a brief overview of the treatment. Medical Principles and Practice, 27(6), 501-507.
  • 4. Sparks, J.A. (2019). Rheumatoid Arthritis. Ann Intern Med. 170(1), ITC1-ITC16.
  • 5. Pincus, T., O'Dell, J. R., & Kremer, J. M. (1999). Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Annals of internal medicine, 131(10), 768-774.
  • 6. Silman, A. J., MacGregor, A. J., Thomson, W., Holligan, S., Carthy, D., Farhan, A., & Ollier, W. E. R. (1993). Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Rheumatology, 32(10), 903-907.
  • 7. Kłodziński, Ł., & Wisłowska, M. (2018). Comorbidities in rheumatic arthritis. Reumatologia/Rheumatology, 56(4), 228-233.
  • 8. Gregersen, P. K., Silver, J., & Winchester, R. J. (1987). The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis & Rheumatism, 30(11), 1205-1213.
  • 9. Weyand, C. M., Hicok, K. C., Conn, D. L., & Goronzy, J. J. (1992). The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Annals of internal medicine, 117(10), 801-806.
  • 10. du Teil Espina, M., Gabarrini, G., Harmsen, H. J., Westra, J., van Winkelhoff, A. J., & van Dijl, J. M. (2019). Talk to your gut: the oral-gut microbiome axis and its immunomodulatory role in the etiology of rheumatoid arthritis. FEMS microbiology reviews, 43(1), 1-18.